Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Disease evolution and outcomes in familial AML with germline CEBPA mutations

Blood (2015) 126 (10): 1214–1223.

https://doi.org/10.1182/blood-2015-05-647172

Published: 2015

Includes: Supplemental data

Journal Articles

The Introduction of Novel Agents Improves Outcomes of Young Patients with Myeloma (MM) Treated with Autologous Stem Cell Transplant (ASCT)

Radovan Saso, MD, MPhil, PhD, Kevin D Boyd, MB.BS, Kabir Mohammed, Ping Wu, Jennifer Treleaven, Faith E. Davies, MD, Gareth J Morgan, MD, PhD

Blood (2010) 116 (21): 1348.

https://doi.org/10.1182/blood.V116.21.1348.1348

Published: 2010

Journal Articles

Maintenance Chemotherapy (MC) after Autotransplantation in First-Remission Acute Lymphoblastic Leukemia (ALL): Single-Center Experience of 100 Patients.

Bhawna Sirohi, Ray Powles, Jennifer Treleaven, Samar Kulkarni, Radovan Saso, Mike Potter, Mark Ethell, Gareth Morgan, Seema Singhal, Jayesh Mehta

Blood (2007) 110 (11): 2874.

https://doi.org/10.1182/blood.V110.11.2874.2874

Published: 2007

Journal Articles

Incidence of Second Malignant Neoplasms (SMN) after Haematopoetic Stem Cell Transplant.

Samar Kulkarni, MRCP, Michael Potter, MRCPath, Mark Ethell, PRCPath, Radovan Saso, PhD, Jennifer Treleaven, FRCPath, Joy Brennan, BSc, Pawel Kaczmarek, MRCP, Prashant Hiwarkar, MRCP, Pamala Kanagasabapathy, MRCP, Caroline Alvares, MRCPath, Clive Horton, PhD, Raymond Powles, FRCP, Frank Saran, FRCR, Gareth Morgan, FRCPath

Blood (2006) 108 (11): 551.

https://doi.org/10.1182/blood.V108.11.551.551

Published: 2006

Journal Articles

Lymphocyte Count on Day 56 Predicts for Reduced Risk of Infection Related Mortality Following Non-Myeloablative Allogeneic Haematopoietic Stem Cell Transplantation.

Caroline Alvares, MRCPath, Samar Kulkarni, MRCP, Pawel Kaczmarek, PhD, Radovan Saso, PhD, Helena Woods, Joy Brennan, BSc, Clive Horton, PhD, Jennifer Treleaven, FRCPath, Mark Ethell, MRCPath, Claire Dearden, MRCPath, Gareth Morgan, FRCPath, Michael Potter, FRCPath

Blood (2006) 108 (11): 5324.

https://doi.org/10.1182/blood.V108.11.5324.5324

Published: 2006

Journal Articles

Outcomes of Patients with Hematological Malignancies Admitted to Critical Care.

Girish Ravindranathan, MRCP, Vaia Grigoriadou, MRCP, Radovan Saso, MD, PhD, Shelley Dolan, MSc, PhD, Mark Ethell, MRCP, MRCPath, Michael Potter, FRCP, FRCPath, Jennifer Treleaven, FRCP, FRCPath, Gareth Morgan, FRCP, FRCPath

Blood (2006) 108 (11): 5289.

https://doi.org/10.1182/blood.V108.11.5289.5289

Published: 2006

Journal Articles

Prophylactic Defibrotide in Allogeneic Stem Cell Transplantation: Low Morbidity and Zero Mortality from Veno-Occlusive Disease.

Fiona L. Dignan, BSc, MRCP, Dorothy Gujral, MRCP, Mark E. Ethell, MD MRCP MRCPath, Jennifer Treleaven, FRCP FRCPath, Gareth Morgan, PhD FRCP FRCPath, Michael Potter, PhD FRCP FRCPath

Blood (2006) 108 (11): 2968.

https://doi.org/10.1182/blood.V108.11.2968.2968

Published: 2006

Journal Articles

Pregnancy Outcome Following Haematopoietic Stem Cell Transplantation.

Samar Kulkarni, MRCP, Mark Ethell, MRCPath, Jennifer Treleaven, FRCPath, Radovan Saso, PhD, Joy Brennan, BsC, Pawel Kaczmarek, PhD, Caroline Alvares, MRCPATH, Clive Horton, PhD, Frank Saran, FRCR, Pamala Kanagasabapathy, MRCP, Prashant Hiwarkar, MRCP, Stella Appiah-Cubi, MRCP, Moez Dungarwala, MRCP, Raymond Powles, FRCP, Gareth Morgan, FRCPath, Michael Potter, FRCPath

Blood (2006) 108 (11): 3367.

https://doi.org/10.1182/blood.V108.11.3367.3367

Published: 2006

Journal Articles

A Comparative Analysis of Outcomes in Primary Myelodysplastic Syndrome (MDS) and Therapy-Related MDS Reveals Two Subgroups with Differing Risk Profiles: Implications for the Application of a Prognostic Classification.

Caroline Alvares, Sue Ashley, Radovan Saso, Gita Patel, Amrana Qureshi, Michael Potter, Mark Ethell, Jennifer Treleaven, Claire Dearden, Gareth Morgan

Blood (2005) 106 (11): 2532.

https://doi.org/10.1182/blood.V106.11.2532.2532

Published: 2005

Journal Articles

Responses to Induction Chemotherapy and High Dose Melphalan Can Be Incorporated within a Risk Stratification Model and Help to Identify Myeloma Patients Who May Benefit from Novel Therapies.

Caroline L. Alvares, Faith E. Davies, Clive Horton, Gita Patel, Roslin Zuha, Alex Gatt, Radovan Saso, Jennifer Treleaven, Mark Ethell, Mike Potter, Claire Dearden, Gareth J. Morgan

Blood (2004) 104 (11): 2394.

https://doi.org/10.1182/blood.V104.11.2394.2394

Published: 2004

Journal Articles

The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia

Ray Powles, Bhawna Sirohi, Jennifer Treleaven, Samar Kulkarni, Diana Tait, Seema Singhal, Jayesh Mehta

Blood (2002) 100 (5): 1641–1647.

https://doi.org/10.1182/blood-2002-03-0776

Published: 2002

Journal Articles

Identification of Patients Who May Benefit From Prophylactic Immunotherapy After Bone Marrow Transplantation for Acute Myeloid Leukemia on the Basis of Lymphocyte Recovery Early After Transplantation

Ray Powles, Seema Singhal, Jennifer Treleaven, Samar Kulkarni, Clive Horton, Jayesh Mehta

Blood (1998) 91 (9): 3481–3486.

https://doi.org/10.1182/blood.V91.9.3481

Published: 1998

Journal Articles

Leukocyte Recovery and Early Treatment-Related Mortality After Bone Marrow Transplantation

Jayesh Mehta, Ray Powles, Clive Horton, Jennifer Treleaven, Seema Singhal

Blood (1997) 89 (11): 4237.

https://doi.org/10.1182/blood.V89.11.4237

Published: 1997

NARROW

Disease evolution and outcomes in familial AML with germline CEBPA mutations

The Introduction of Novel Agents Improves Outcomes of Young Patients with Myeloma (MM) Treated with Autologous Stem Cell Transplant (ASCT)

Maintenance Chemotherapy (MC) after Autotransplantation in First-Remission Acute Lymphoblastic Leukemia (ALL): Single-Center Experience of 100 Patients.

Incidence of Second Malignant Neoplasms (SMN) after Haematopoetic Stem Cell Transplant.

Lymphocyte Count on Day 56 Predicts for Reduced Risk of Infection Related Mortality Following Non-Myeloablative Allogeneic Haematopoietic Stem Cell Transplantation.

Outcomes of Patients with Hematological Malignancies Admitted to Critical Care.

Prophylactic Defibrotide in Allogeneic Stem Cell Transplantation: Low Morbidity and Zero Mortality from Veno-Occlusive Disease.

Pregnancy Outcome Following Haematopoietic Stem Cell Transplantation.

A Comparative Analysis of Outcomes in Primary Myelodysplastic Syndrome (MDS) and Therapy-Related MDS Reveals Two Subgroups with Differing Risk Profiles: Implications for the Application of a Prognostic Classification.

Responses to Induction Chemotherapy and High Dose Melphalan Can Be Incorporated within a Risk Stratification Model and Help to Identify Myeloma Patients Who May Benefit from Novel Therapies.

The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia

Identification of Patients Who May Benefit From Prophylactic Immunotherapy After Bone Marrow Transplantation for Acute Myeloid Leukemia on the Basis of Lymphocyte Recovery Early After Transplantation

Leukocyte Recovery and Early Treatment-Related Mortality After Bone Marrow Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only